Development of poly-(d,l-lactide–coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis

Cleland, Jeffrey L.; Duenas, Eileen; Park, Ann; Daugherty, Ann L.; Kahn, Jeanne; Kowalski, J.; Cuthbertson, Andrew G. S.

doi:10.1016/s0168-3659(01)00258-9

Cited by 192 publications

(119 citation statements)

References 22 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…For the Gd-DTPA, 54% was released by day 1, 0.2%/day was released during the slow steady-state phase (days 2-16), and 5%/day was released during the rapid steady-state phase (days 18 -24). For the VEGF, 3% was released by day 1, 0.1%/day was released during the slow steady-state phase (days [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20], and 6%/day was released during the rapid steady-state phase (days 24 -35). The release of VEGF slightly lags that of Gd-DTPA.…”

Section: Release Kineticsmentioning

confidence: 99%

“…One application of biodegradable microspheres that is being actively explored is the delivery of angiogenic factors to treat ischemia (5,6). Angiogenic factors such as vascular endothelial growth factor (VEGF) have promising applications in treating ischemic disease, and it has been demonstrated that local, controlled delivery of VEGF protein can be an effective means of inducing neovascularization and promoting tissue perfusion (7).…”

mentioning

confidence: 99%

See 1 more Smart Citation

In vitro release of vascular endothelial growth factor from gadolinium‐doped biodegradable microspheres

Faranesh

Nastley

Cruz

et al. 2004

Magnetic Resonance in Med

View full text Add to dashboard Cite

A drug delivery vehicle was constructed that could be visualized noninvasively with MRI. The biodegradable polymer poly(DL-lactic-co-glycolic acid) (PLGA) was used to fabricate microspheres containing vascular endothelial growth factor (VEGF) and the MRI contrast agent gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA). The microspheres were characterized in terms of size, drug and contrast agent encapsulation, and degradation rate. The PLGA microspheres had a mean diameter of 48 ؎ 18 m. The gadolinium loading was 17 ؎ 3 g/mg polymer and the VEGF loading was 163 ؎ 22 ng/mg polymer. Electron microscopy revealed that the Gd was dispersed throughout the microspheres and it was confirmed that the Gd loading was sufficient to visualize the microspheres under MRI. VEGF and Gd-DTPA were released from the microspheres in vitro over a period of ϳ6 weeks in three phases: a burst, followed by a slow steady-state, then a rapid steady-state. Biodegradable Gd-doped microspheres can be effectively used to deliver drugs in a sustained manner, while being monitored noninvasively with MRI.

show abstract

Section: Release Kineticsmentioning

confidence: 99%

mentioning

confidence: 99%

In vitro release of vascular endothelial growth factor from gadolinium‐doped biodegradable microspheres

Faranesh

Nastley

Cruz

et al. 2004

Magnetic Resonance in Med

View full text Add to dashboard Cite

show abstract

“…It has already been reported that injectable systems made of nano and microparticles could be applied as carriers of different drugs and bioactive agents within the field of tissue engineering (e.g. differentiation agents and growth factors [39,40]). Dexamethasone (DEX) has been widely used in clinical applications to treat immuno-disorders [41,42], but a more specific and common use has been the control of the inflammatory response and tissue repair during organ transplantation [43].…”

Section: Introductionmentioning

confidence: 99%

Preparation and characterization of starch-poly-ε-caprolactone microparticles incorporating bioactive agents for drug delivery and tissue engineering applications

et al. 2009

View full text Add to dashboard Cite

One limitation associated with the delivery of bioactive agents concerns the short half-life of these molecules when administered intravenously, which results in their loss from the desired site. Incorporation of bioactive agents into depot vehicles provides a means to increase their persistence at the disease site. Major issues are involved in the development of a proper carrier system able to deliver the correct drug, at the desired dose, place and time. In this work, starch-poly-e-caprolactone (SPCL) microparticles were developed for use in drug delivery and tissue engineering (TE) applications. SPCL microparticles were prepared by using an emulsion solvent extraction/evaporation technique, which was demonstrated to be a successful procedure to obtain particles with a spherical shape (particle size between 5 and 900 lm) and exhibiting different surface morphologies. Their chemical structure was confirmed by Fourier transform infrared spectroscopy. To evaluate the potential of the developed microparticles as a drug delivery system, dexamethasone (DEX) was used as model drug. DEX, a well-known component of osteogenic differentiation media, was entrapped into SPCL microparticles at different percentages up to 93%. The encapsulation efficiency was found to be dependent on the polymer concentration and drug-to-polymer ratio. The initial DEX release seems to be governed mainly by diffusion, and it is expected that the remaining DEX will be released when the polymeric matrix starts to degrade. In this work it was demonstrated that SPCL microparticles containing DEX can be successfully prepared and that these microparticular systems seem to be quite promising for controlled release applications, namely as carriers of important differentiation agents in TE.

show abstract

“…DNA has also been formulated with the synthetic, biodegradable polymer, poly(lactide-co-glycolide) (PLG) to generate microparticles capable of sustained gene delivery and expression. [5][6][7] PLG, which has a history of safe application in humans, 8 has been used extensively in the development of vaccine technology, [9][10][11] and may be loaded with biologically active molecules of widely different molecular size including insulin, 12 prolidase, 13 camptothesin 14 and rhVEGF. 15 pDNA encapsulated in PLG remains stable, and protected from enzymatic degradation.…”

Section: Introductionmentioning

confidence: 99%

Poly (D, L-lactide-co-glycolide)/DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo

et al. 2003

View full text Add to dashboard Cite

Development of poly-(d,l-lactide–coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis

Cited by 192 publications

References 22 publications

In vitro release of vascular endothelial growth factor from gadolinium‐doped biodegradable microspheres

In vitro release of vascular endothelial growth factor from gadolinium‐doped biodegradable microspheres

Preparation and characterization of starch-poly-ε-caprolactone microparticles incorporating bioactive agents for drug delivery and tissue engineering applications

Poly (D, L-lactide-co-glycolide)/DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo

Contact Info

Product

Resources

About